Treace generated 62519000 in Q4 2025 revenue, down 9% year-over-year, with gross margin of 80.6% and net loss of 9394000, while delivering adjusted EBITDA of 6185000.

Treace Medical Concepts delivered solid financial results in the second quarter of 2025, with revenue increasing by 7% year-over-year to $47.4 million. The company significantly improved its net loss by 18% and adjusted EBITDA by 58%, demonstrating progress in its strategic initiatives and expanded product portfolio.

Treace Medical Concepts reported solid growth in the first quarter of 2025 with a 3% increase in revenue to $52.6 million and significant improvements in adjusted EBITDA and net loss compared to the same period in the previous year. The company also expanded its bunion technology portfolio with new product launches and continued to build clinical evidence.

Treace Medical Concepts reported a 10% increase in revenue for Q4 2024, reaching $68.7 million, and significantly improved its net loss and Adjusted EBITDA compared to the same period in 2023, driven by product mix shift, adoption of newer technologies, and increased bunion procedure kits sold.

Treace Medical Concepts reported an 11% increase in revenue to $45.1 million for Q3 2024 compared to $40.8 million in Q3 2023. The net loss improved to ($15.4) million from ($17.5) million year-over-year, and the Adjusted EBITDA loss improved 45% to ($5.1) million.

Treace Medical Concepts reported a 6% increase in revenue for the second quarter of 2024, reaching $44.5 million. The company's gross margin was 80.2%. The company is reaffirming full-year 2024 revenue guidance of $201 million to $211 million.

Treace Medical Concepts reported a 21% increase in revenue to $51.1 million for Q1 2024 compared to the same period in 2023. The company's gross margin was 80.2%. Net loss attributable to common stockholders was ($18.7) million, and the Adjusted EBITDA loss improved to ($8.3) million.

Treace Medical Concepts reported a strong fourth quarter and full-year 2023, with revenue increasing 25% in Q4 and 32% for the full year. The company saw growth in Lapiplasty® procedure kit sales, blended average selling prices, and active surgeon additions. Treace is guiding for continued revenue growth in 2024 and expects to make significant progress towards Adjusted EBITDA breakeven.

Treace Medical Concepts reported a revenue of $40.8 million for Q3 2023, a 23% increase year-over-year. The company's gross margin was 80.4%. They are updating full-year 2023 revenue guidance to $182 million to $186 million.

Treace Medical Concepts reported a strong second quarter with a 40% increase in revenue to $42.0 million compared to the same period last year. The company also saw an increase in gross profit to $34.3 million and made progress on adjusted EBITDA. They are raising full-year 2023 revenue guidance to $191 million to $197 million.

Treace Medical Concepts reported a 45% increase in revenue to $42.2 million for the first quarter of 2023 compared to the same period last year. The increase was driven by an increased number of Lapiplasty® procedure kits sold and increased blended average selling prices. Gross margin was 80.9%.

Treace Medical Concepts reported a strong fourth quarter in 2022, with revenue increasing by 49% compared to the same period last year. The company's gross margin remained high at 80.4%, and there was increased adoption of Lapiplasty procedure.

Treace Medical Concepts reported a 53% increase in revenue for the third quarter of 2022, reaching $33.1 million. The growth was driven by an increased number of Lapiplasty® procedure kits sold and higher average selling prices. The company is raising its full-year 2022 revenue guidance to $135 million to $138 million.

Treace Medical Concepts reported a strong second quarter with a 45% increase in revenue, driven by an expanded surgeon customer base and increased adoption of newer technologies. The company is raising its full-year 2022 revenue guidance to $130 million to $134 million.

Treace Medical Concepts reported a strong start to 2022, with revenue increasing by 55% compared to the same period last year. The company is raising its full year 2022 revenue guidance to $128 million to $133 million.

Treace Medical Concepts reported a strong fourth quarter with a 39% increase in revenue compared to the same period last year, driven by the bunion-focused direct sales channel and direct-to-consumer programs. The company's gross margin also increased to 81.1%.

Treace Medical Concepts reported a revenue of $21.6 million for Q3 2021, a 52% increase compared to Q3 2020. The company launched the Adductoplasty™ System and treated the first patient in the Mini3D™ clinical study. They are reaffirming revenue guidance to be in the range of $90 million to $95 million for the full year 2021.

Treace Medical Concepts reported strong second-quarter results, driven by increased surgeon utilization and customer base expansion. Revenue reached $20.7 million, a 167% increase year-over-year, with a gross margin of 80.9%. The company now expects full-year revenue to range from $90 million to $95 million.

Treace Medical Concepts reported a strong start to 2021 with a 66% increase in revenue compared to the same period last year. The company's gross margin also improved, and they completed their initial public offering.